Probiotics and ileitis: Could augmentation of TNF/NFκB activity be the answer?

Gut Microbes

Volumn 1, Issue 3, 2010, Pages 1-4

  Jobin, Christian ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Gene regulation; Inflammation; Microbiome; Probiotics; Transcription

Indexed keywords

3 (4 TERT BUTYLPHENYLSULFONYL) 2 PROPENENITRILE; ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CYCLOSPORIN; GLUCOCORTICOID; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; LACTIC ACID; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PROBIOTIC AGENT; SALAZOSULFAPYRIDINE; TACROLIMUS; TOLL LIKE RECEPTOR 5; TUMOR NECROSIS FACTOR ALPHA; VSL3;

ACTINOBACTERIA; ARTICLE; BACTEROIDES; COLON MUCOSA; CYTOKINE PRODUCTION; DRUG EFFICACY; FIRMICUTES; ILEITIS; IMMUNOCOMPETENT CELL; INTESTINE EPITHELIUM CELL; INTESTINE FLORA; MUCOSAL IMMUNITY; NONHUMAN; PROTEOBACTERIA; PUBLICATION1; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; GENETICS; HUMAN; IMMUNOLOGY;

HUMANS; ILEITIS; NF-KAPPA B; PROBIOTICS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77954820050     PISSN: 19490976     EISSN: 19490984     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003; 3:521-33.
2. Hilsden RJ, Verhoef MJ, Rasmussen H, Porcino, A, DeBruyn JCC. Use of complementary and alternative medicine by patients with inflammatory bowel disease. Inflamm Bowel Dis 2010. In press
3. Nahin RL, Barnes PM, Stussman BJ, Bloom B. Costs of complementary and alternative medicine (CAM) and frequency of visits to CAM practitioners: United States, 2007. Natl Health Stat Report 2009; 1-14.
4. Frank DN, St. Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characarization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 2007; 104:13780-5.
5. Neish AS. Microbes in gastrointestinal health and disease. Gastroenterology 2009; 136:65-80.
6. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464:59-65.
7. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444:1027-31.
8. Mullard A. Microbiology: the inside story. Nature 2008; 453:578-80.
9. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. Nature 2007; 449:804-10.
10. Takaishi H, Matsuki T, Nakazawa A, Takada T, Kado S, Asahara T, et al. Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. Int J Med Microbiol 2008; 298:463-72.
11. Ott SJ, Musfeldt M, Wenderoth DF, Hampe J, Brant O, Folsch UR, et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 2004; 53:685-93.
12. Ott SJ, Plamondon S, Hart A, Begun A, Rehman A, Kamm MA, Schreiber S. Dynamics of the mucosaassociated flora in ulcerative colitis patients during remission and clinical relapse. J Clin Microbiol 2008; 46:3510-3.
13. Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 2006; 55:205-11.
14. Garrett WS, Lord GM, Punit S, Lugo-Villarino G, Mazmanian SK, Ito S, et al. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell 2007; 131:33-45.
15. Turnbaugh PJ, Backhed F, Fulton L, Gordon JI. Dietinduced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 2008; 3:213-23.
16. Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, Srinivasan S, et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010; 328:228-31.
17. Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001; 121:580-91.
18. Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak RN. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999; 116:1107-14.
19. Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005; 100:1539-46.
20. Huynh HQ, deBruyn J, Guan L, Diaz H, Li M, Girgis S, et al. Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study. Inflamm Bowel Dis 2009; 15:760-8.
21. Sood A, Midha V, Makharia GK, Ahuja V, Singal D, Goswami P, Tandon RK. The Probiotic Preparation, VSL#3, Induces Remission in Patients With Mildto-Moderately Active Ulcerative Colitis. Clin Gastroenterol Hepatol 2009.
22. Chapman TM, Plosker GL, Figgitt DP. Spotlight on VSL#3 probiotic mixture in chronic inflammatory bowel diseases. BioDrugs 2007; 21:61-3.
23. Prisciandaro L, Geier M, Butler R, Cummins A, Howarth G. Probiotics and their derivatives as treatments for inflammatory bowel disease. Inflamm Bowel Dis 2009.
24. Marteau PR, de Vrese M, Cellier CJ, Schrezenmeir J. Protection from gastrointestinal diseases with the use of probiotics. Am J Clin Nutr 2001; 73:430-6.
25. Ahn C, Stiles ME. Antibacterial activity of lactic acid bacteria isolated from vacuum-packaged meats. J Appl Bacteriol 1990; 69:302-10.
26. Corr SC, Li Y, Riedel CU, O'Toole PW, Hill C, Gahan CG. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci USA 2007; 104:7617-21.
27. Okamoto T, Sasaki M, Tsujikawa T, Fujiyama Y, Bamba T, Kusunoki M. Preventive efficacy of butyrate enemas and oral administration of Clostridium butyricum M588 in dextran sodium sulfate-induced colitis in rats. J Gastroenterol 2000; 35:341-6.
28. Lin MY, Chang FJ. Antioxidative effect of intestinal bacteria Bifidobacterium longum ATCC 15708 and Lactobacillus acidophilus ATCC 4356. Dig Dis Sci 2000; 45:1617-22.
29. Isolauri E, Majamaa H, Arvola T, Rantala I, Virtanen E, Arvilommi H. Lactobacillus casei strain GG reverses increased intestinal permeability induced by cow milk in suckling rats. Gastroenterology 1993; 105:1643-50.
30. Pessi T, Sutas Y, Marttinen A, Isolauri E. Probiotics reinforce mucosal degradation of antigens in rats: implications for therapeutic use of probiotics. J Nutr 1998; 128:2313-8.
31. Pessi T, Sutas Y, Saxelin M, Kallioinen H, Isolauri E. Antiproliferative effects of homogenates derived from five strains of candidate probiotic bacteria. Appl Environ Microbiol 1999; 65:4725-8.
32. Madsen K. Probiotics and the immune response. J Clin Gastroenterol 2006; 40:232-4.
33. Neish AS, Gewirtz AT, Zeng H, Young AN, Hobert ME, Karmali V, et al. Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination. Science 2000; 289:1560-3.
34. Pagnini C, Saeed R, Bamias G, Arseneau KO, Pizarro TT, Cominelli F. Probiotics promote gut health through stimulation of epithelial innate immunity. Proc Natl Acad Sci USA 2010; 107:454-9.
35. Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986; 46:705-16.
36. Neurath MF, Becker C, Barbulescu K. Role of NFkappaB in immune and inflammatory responses in the gut. Gut 1998; 43:856-60.
37. Jobin C, Sartor RB. NFkappaB signaling proteins as therapeutic targets for inflammatory bowel diseases. Inflamm Bowel Dis 2000; 6:206-13.
38. Jobin C, Sartor RB. The IkappaB/NFkappaB system: a key determinant of mucosal inflammation and protection. Am J Physiol Cell Physiol 2000; 278:451-62.
39. Barnes PJ, Karin M. Nuclear FactorkB, a pivotal transcription factor in chronic inflammatory diseases. New Eng J Med 1997; 336:1066-71.
40. Karrasch T, Jobin C. NFkappaB and the intestine: friend or foe? Inflamm Bowel Dis 2008; 14:114-24.
41. Cominelli F. Cytokine-based therapies for Crohn's disease-new paradigms. N Engl J Med 2004; 351:2045-8.
42. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118:285-96.
43. Steinbrecher KA, Harmel-Laws E, Sitcheran R, Baldwin AS. Loss of Epithelial RelA Results in Deregulated Intestinal Proliferative/Apoptotic Homeostasis and Susceptibility to Inflammation. J Immunol 2008; 180:2588-99.
44. Nenci A, Becker C, Wullaert A, Gareus R, van Loo G, Danese S, et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 2007; 446:557-61.
45. Egan LJ, Eckmann L, Greten FR, Chae S, Li ZW, Myhre GM, et al. IkappaB-kinasebeta-dependent NFkappaB activation provides radioprotection to the intestinal epithelium. Proc Natl Acad Sci USA 2004; 101:2452-7.
46. Chen LW, Egan L, Li ZW, Greten FR, Kagnoff MF, Karin M. The two faces of IKK and NFkappaB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemiareperfusion. Nat Med 2003; 9:575-81.
47. Karrasch T, Jobin C. Wound healing responses at the gastrointestinal epithelium: a close look at novel regulatory factors and investigative approaches. Z Gastroenterol 2009; 47:1221-9.
48. Dave SH, Tilstra JS, Matsuoka K, Li F, Karrasch T, Uno JK, et al. Amelioration of Chronic Murine Colitis by Peptide-Mediated Transduction of the I{kappa}B Kinase Inhibitor NEMO Binding Domain Peptide. J Immunol 2007; 179:7852-9.
49. Eckmann L, Nebelsiek T, Fingerle AA, Dann SM, Mages J, Lang R, et al. Opposing functions of IKKbeta during acute and chronic intestinal inflammation. Proc Natl Acad Sci USA 2008; 105:15058-63.
50. Uronis JM, Arthur JC, Keku T, Fodor A, Carroll IM, Cruz ML, et al. Gut Microbial Diversity is Reduced by the Probiotic VSL#3 and Correlates with Decreased TNBS-Induced Colitis Inflamm Bowel Dis 2010; in press
51. Martinez-Medina M, Aldeguer X, Gonzalez-Huix F, Acero D, Garcia-Gil LJ. Abnormal microbiota composition in the ileocolonic mucosa of Crohn's disease patients as revealed by polymerase chain reactiondenaturing gradient gel electrophoresis. Inflamm Bowel Dis 2006; 12:1136-45.
52. Yan F, Cao H, Cover TL, Whitehead R, Washington MK, Polk DB. Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology 2007; 132:562-75.